Laureyssen, Celeste
Küçükali, Fahri
Van Dongen, Jasper
Gawor, Klara
Tomé, Sandra O.
Ronisz, Alicja
Otto, Markus
von Arnim, Christine A. F.
Van Damme, Philip
Vandenberghe, Rik
Thal, Dietmar Rudolf
Sleegers, Kristel https://orcid.org/0000-0002-0283-2332
Funding for this research was provided by:
Fund for Scientific Research Flanders (FWO G065721N)
FWO (FWO G065721N)
Onderzoeksraad, KU Leuven (C14/22/132, C14/22/132)
Alzheimer's Association (22-AAIIA-963171)
BrightFocus Foundation (A2022019F)
BOF UAntwerp (49758)
Article History
Received: 16 July 2024
Revised: 8 October 2024
Accepted: 8 October 2024
First Online: 18 October 2024
Declarations
:
: DRT collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE-Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium). DRT and KS are members of Acta Neuropathologica editorial board. They were not involved in the assessment or decision-making process for this manuscript. CAFvA received honoraria from serving on the scientific advisory board of Biogen, Roche, Novo Nordisk, Biontech, Lilly, Dr. Willmar Schwabe GmbH &Co. KG, and MindAhead UG and has received funding for travel and speaker honoraria from Biogen, Lilly, Novo Nordisk, Roche diagnostics AG, Novartis, Medical Tribune Verlagsgesellschaft mbH, Landesvereinigung für Gesundheit und Akademie für Sozialmedizin Niedersachsen e. V., FomF GmbH | Forum für medizinische Fortbildung and Dr. Willmar Schwabe GmbH &Co. KG has received research support from Roche diagnostics AG. RVs institution has clinical trial agreements (RV as PI) with Alector, Biogen, Denali, J&J, EliLilly, and UCB and consultancy agreements (RV as DSMB member) with AC Immune. The other authors have nothing to disclose.
: Tissue collection was performed in accordance with the local ethical committee guidelines and laws regarding the use of human tissue for research. The research protocol for the current study was approved by the ethical committees of the UZ/KU Leuven and UZA/University of Antwerp.